Results 131 to 140 of about 7,703 (180)

Chest CT in Testicular Mass Evaluation: A Stepwise Approach to Minimize Radiation Exposure.

Urol Int
Eigner E, Malshy K, Fazaa N, Nsair A, Atallah M, Amiel GE, Hoffman A.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Survival differences in non-seminoma testis cancer patients according to race/ethnicity

Cancer Epidemiology
Historic evidence suggests that non-Caucasian race/ethnicity predisposes to higher testis cancer-specific mortality (CSM) in non-seminoma. However, it is unknown, whether higher CSM in non-Caucasians applies to Hispanics or Asians or African-Americans, or all of the above groups. In contemporary patients, we tested whether CSM is higher in these select
Reha-Baris İncesu, Simone Morra
exaly   +4 more sources

Orchidopexy and transformation of seminoma to non-seminoma

Lancet, The, 1992
R T D Oliver, J P Blandy, R T Oliver
exaly   +3 more sources

Chemotherapy and radiotherapy in advanced testicular non-seminoma

Radiotherapy and Oncology, 1984
G Duchesne, M J Peckham
exaly   +2 more sources

Radiation Therapy of Testicular Non-Seminomas

Journal of Urology, 1982
The prognosis of 121 patients with a non-seminoma testicular tumor MTI or MTU was assessed. The clinical lymph node involvement and the T-category of the primary had a significant bearing on prognosis, which is completely determined by pulmonary relapse. The low-risk group (9% pulmonary relapse, all curable) is characterized by a primary category T1 or
B, van der Werf-Messing, W C, Hop
openaire   +2 more sources

Is there a Role for Radiotherapy in the Management of Testicular Non‐Seminomas?

Australasian Radiology, 1984
SUMMARYIn recent years several new treatment options have become available in the management of Stage I and II nonseminomatous tumours of the testis as a result of more accurate staging of tumour extent and the development of curative chemotherapy.
K W, Tiver, A O, Langlands
openaire   +2 more sources

Conditional survival of stage III non-seminoma testis cancer patients

Urologic Oncology: Seminars and Original Investigations, 2023
In many primaries other than non-seminoma testis cancer, the risk of death due to cancer decreases with increasing disease-free interval duration after initial diagnosis and treatment. This effect is known as conditional survival and is relatively unexplored in stage III non-seminoma patients, where it may matter most in clinical decision-making.
Incesu R. -B., Barletta F., Tappero S., Morra S., Garcia C. C., Scheipner L., Piccinelli M. L., Tian Z., Saad F., Shariat S. F., de Cobelli O., Ahyai S., Chun F. K. H., Longo N., Terrone C., Briganti A., Tilki D., Graefen M., Karakiewicz P. I.   +18 more
openaire   +4 more sources

Histopathological and molecular features of late relapses in non‐seminomas

BJU International, 2010
Study Type – Therapy (case series) Level of Evidence 4 What's known on the subject? and What does the study add? Late relapses from germ cell tumors respond poorly to systemic chemotherapy.
Mayer, Frenchey, Wermann, H, Albers, P, Stoop, Hans, Gillis, Ad, Hartmann, JT, Bokemeyer, CC, Oosterhuis, Wolter, Looijenga, LHJ (Leendert), Honecker, F   +9 more
openaire   +3 more sources

Initial chemotherapy for stage II testicular non-seminoma

World Journal of Urology, 1994
A retrospective survival analysis was performed on 287 patients treated with chemotherapy following orchidectomy for stage II testicular non-seminoma between 1982 and 1986 at a number of centres in the United Kingdom and 1 centre in Norway. A total of 80 patients had lymphadenectomy for a residual mass after chemotherapy.
A, Horwich, S, Stenning
openaire   +2 more sources